- Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced results from the Phase 1 trial studying the effect of emraclidine on 24-hour ambulatory blood pressure over eight weeks in schizophrenia patients.
- The trial’s objective was to accurately characterize any potential blood pressure effect for both doses of emraclidine studied (10 and 30 mg QD).
- On the primary endpoint, emraclidine demonstrated a mean change from baseline at week eight in 24-hour ambulatory systolic blood pressure (SBP) of -2.7 mmHg for the 10 mg QD group and -0.4 mmHg for the 30 mg QD group.
- Related: Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why.
- The upper bound was -0.3 mmHg for the 10 mg QD group and 2.1 mmHg for the 30 mg QD group.
- As a result, the trial ruled out an increase in blood pressure for both doses.
- The trial’s secondary endpoints demonstrated findings consistent with the primary endpoint, corroborating the overall trial results.
- Emraclidine was generally well-tolerated in this trial, with a side effect profile consistent with prior trials.
- This ambulatory blood pressure monitoring trial was designed in line with FDA guidance.
- Price Action: CERE shares are up 30.34% at $33.04 on the last check Monday.
Bill Gates Says ‘Bad Guys Will Be More Productive’ As Sam Altman And Other Leaders Discuss Potential Impact Of AI On US Presidential Election
Altman emphasized OpenAI's focus on minimizing the potential for political misuse of its AI tools. He also mentioned that the company will soon release a tool for testing that can identify AI-generated content and digitally watermark material generated by Dall-E.
